Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Read more...
Read More Details
Finally We wish PressBee provided you with enough information of ( Eli Lilly was hoping for even greater weight loss drug demand )
Also on site :
- Saylor's Bitcoin tweet sparks controversy: "Fight for Bitcoin”
- Oil Markets Brace for Impact After U.S. Attacks Iran Facilities
- 耶魯大學醫學院宣佈成立耶魯生物醫學成像研究所 Yale Biomedical Imaging Institute